Politician trade (House)

Eli Lilly (LLY): Rep. Josh Gottheimer (NJ05) disclosed a partial sale $1K–$15K

Rep. Josh Gottheimer (NJ05) disclosed a partial sale of Eli Lilly in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
36 days
Disclosure lag
Traded
Dec 9, 2024
Disclosed
Jan 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  2. Oct 18, 2024FDAFDA drug approval: Zepbound
  3. Oct 30, 2024CongressDisclosed purchase of LLY — reported range $15,001 - $50,000
  4. Nov 8, 2024InsiderOfficer sold ~$723K of LLY shares in the open market
  5. Nov 8, 2024CongressDisclosed sale of LLY — reported range $15,001 - $50,000
  6. Nov 13, 2024FDAFDA drug approval: Verzenio
  7. Nov 14, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  8. Nov 19, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  9. Dec 9, 2024 · this disclosureCongressDisclosed partial sale of LLY — reported range $1,001 - $15,000

What came next

  1. Dec 10, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  2. Dec 11, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  3. Dec 12, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  4. Dec 13, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  5. Dec 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  6. Dec 18, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  7. Dec 20, 2024FDAFDA drug approval: Zepbound
  8. Dec 24, 2024CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  9. Jan 8, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  10. Jan 15, 2025FDAFDA drug approval: Omvoh
  11. Jan 15, 2025FDAFDA drug approval: Omvoh
  12. Jan 21, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  13. Jan 22, 2025CongressDisclosed purchase of LLY — reported range $50,001 - $100,000
  14. Jan 27, 2025FDAFDA drug approval: Cyramza
  15. Feb 6, 2025Insider · 1 personInsiders: 22 sales (~$183.6M)
  16. Feb 10, 2025Insider · 1 personInsiders: 3 sales (~$4.3M)
  17. Feb 10, 2025CongressDisclosed sale of LLY — reported range $50,001 - $100,000
  18. Feb 13, 2025Insider · 1 personInsiders: 7 sales (~$31.2M)
  19. Feb 19, 2025Insider · 1 personInsiders: 4 sales (~$8.8M)
  20. Feb 20, 2025Insider · 1 personInsiders: 4 sales (~$12.9M)
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Rep. Josh Gottheimer (NJ05)

The full history of Rep. Josh Gottheimer (NJ05) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Eli Lilly (LLY) stock, and how much?

Rep. Josh Gottheimer (NJ05) disclosed a partial sale of Eli Lilly in the $1K–$15K range. Reported range, not an exact amount, Joint account.

When did it happen, and when was it made public?

Traded: Dec 9, 2024. Disclosed: Jan 14, 2025. That is 36 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Eli Lilly recently?

For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days. They are listed on the LLY page.

Does this mean LLY stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data